Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I‐Preserve). (23rd May 2014)

• Record Type: Journal Article
• Authors: Böhm, Michael; Perez, Ana‐Cristina; Jhund, Pardeep S.; Reil, Jan C.; Komajda, Michel; Zile, Michael R.; McKelvie, Robert S; Anand, Inder S; Massie, Barry M.; Carson, Peter E.; McMurray, John J. V.; on behalf of the I‐Preserve Committees and Investigators
• Is Part Of: European journal of heart failure. Volume 16:Number 7(2014)
• Page Start: 778
• Page End: 787
• Publication Date: 2014-05-23
• Subjects: Heart failure -- Periodicals; Heart Failure -- Periodicals; Insuffisance cardiaque -- Périodiques; Heart failure; Periodicals; 616.129005
• DOI: 10.1002/ejhf.85
• Languages: English
• ISSNs: 1388-9842

Abstract

<abstract abstract-type="main" id="ejhf85-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ejhf85-sec-0001" sec-type="section"> <title>Background</title> <p id="ejhf85-para-0001">Higher heart rate is associated with poorer outcomes in patients with heart failure and reduced ejection fraction (HF‐REF). Less is known about the association between heart rate and outcomes in patients with heart failure and preserved ejection fraction (HF‐PEF). Therefore, we examined the relationship between heart rate and outcomes in the irbesartan in patients with heart failure and preserved systolic function trial (I‐Preserve) in patients with an ejection fraction >45% aged >60 years.</p> </sec> <sec id="ejhf85-sec-0002" sec-type="section"> <title>Methods and results</title> <p id="ejhf85-para-0002">Heart rate was analysed as both a categorical (tertiles) and continuous variable. Patients in sinus rhythm (<italic>n</italic> = 3271) and atrial fibrillation (<italic>n</italic> = 696) were analysed separately. The outcomes examined were the primary endpoint of the trial (all‐cause death or cardiovascular hospitalization), the composite of cardiovascular death or heart failure hospitalization (and its components) and all‐cause death alone. Higher heart rate was associated with a significantly higher risk of all outcomes studied for patients in sinus rhythm, even after adjustment for other prognostic variables, including <italic>N</italic>‐terminal pro‐B‐type natriuretic peptide. Each standard deviation (12.4 bpm) increase in heart rate was associated with an increase in risk of 13% for cardiovascular death or heart failure hospitalization (<italic>P</italic> = 0.002). No relationship between heart rate and outcomes was observed for patients in atrial fibrillation. Beta‐blocker treatment did not reduce the heart rate–risk relationship.</p> </sec> <sec id="ejhf85-sec-0003" sec-type="section"> <title>Conclusions</title> <p id="ejhf85-para-0003">In patients with heart failure and preserved ejection fraction, heart rate is in sinus rhythm an independent predictor of adverse clinical outcomes and might be a therapeutic target in this syndrome.</p> <p id="ejhf85-para-0004">Clinical Trial Registration – URL <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.clinicaltrials.gov</ext-link>. Unique identifier: NCT 0095238</p> </sec> </abstract>